|
1 Indications And Usage Triumeq Is Indicated For The Treatment Of Human Immunodeficiency Virus Type 1 (hiv-1) Infection In Adults And In Pediatric Patients Weighing At Least 40 Kg. Limitations Of Use: • Triumeq Alone Is Not Recommended In Patients With Resistance-Associated Integrase Substitutions Or Clinically Suspected Integrase Strand Transfer Inhibitor Resistance Because The Dose Of Dolutegravir In Triumeq Is Insufficient In These Subpopulations. See Full Prescribing Information For Tivicay (dolutegravir). Triumeq, A Combination Of Dolutegravir (integrase Strand Transfer Inhibitor [insti]), Abacavir, And Lamivudine (both Nucleoside Analogue Reverse Transcriptase Inhibitors) Is Indicated For The Treatment Of Hiv-1 Infection In Adults And In Pediatric Patients Weighing At Least 40 Kg. ( 1 ) Limitations Of Use: • Triumeq Alone Is Not Recommended In Patients With Resistance-Associated Integrase Substitutions Or Clinically Suspected Integrase Strand Transfer Inhibitor Resistance Because The Dose Of Dolutegravir In Triumeq Is Insufficient In These Subpopulations. See The Dolutegravir Prescribing Information. ( 1 )
|